Dr Maryann Anderson

Doctor Anderson is a hematologist at the Royal Melbourne Hospital and Peter MacCallum Cancer entre specializing in high and low grade lymphomas with a particular interest in early phase clinical trial development. She holds a joint position at the Walter and Eliza Hall Institute as a post-doctoral clinician scientist. Doctor Anderson’s research since 2011 has focused on the development of targeted therapy for the treatment of B cell malignancies. As part of this she has been involved in the development of venetoclax,  the first targeted BCL2 inhibitor, for the use in B cell malignancies. Her work is now focused on identifying biomarkers for venetoclax efficacy, as well as understanding mechanisms for the development of resistance to the agent and identifying rational drug combinations for clinical trial testing.